RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

BACKGROUND: NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a highly selective TRK inhibitor approved to treat patients with TRK fusion cancer, with an objective response rate (ORR) of 78% across multiple non-CNS cancers (McDermott et al, ESMO 2020). We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Perreault, Sébastien, Doz, François, Geoerger, Birgit, Nysom, Karsten, Øra, Ingrid, Boni, Valentina, Chisholm, Julia, DuBois, Steven G, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Kang, Hyoung Jin, Capra, Michael, Schulte, Johannes H, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Rare Tumors/Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168097/
http://dx.doi.org/10.1093/neuonc/noab090.168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168097/
http://dx.doi.org/10.1093/neuonc/noab090.168

Ejemplares similares